Dexcom
(Nasdaq: DXCM)
recently announced the availability of its Dexcom One real-time continuous glucose monitor (CGM) in France.
The availability of the real-time CGM sensor comes via reimbursement. It brings the technology to half a million more people with diabetes in France. The company secured access to the platform for all patients two years and older with type 1 and type 2 diabetes undergoing intensive insulin therapy.
Get the full story at our sister site, Drug Delivery Business News.